BRAIN CANCER
CAT.# FP-045: 1p/19q GENE PROBE
IVD/RUO
BACKGROUND
The most common genetic alteration in oligodendroglioma is the loss of heterozygosity in the long arm (19q) of chromosome 19, which occurs between 50% and 80%, and the most common deletion region is 19q13.3. The second most common is the loss of heterozygosity in the short arm (1p) of chromosome 1, which occurs between 40% and 92%.
PROBE DESCRIPTION
1p/19q deletion probe uses an orange dye to label the short arm p36 region of chromosome 1 and a green dye to label the long arm q13 region of chromosome 19
CLINICAL SIGNIFICANCE
The detection of 1p/19q heterozygous deletion has important implications for clinical treatment guidance and prognosis of oligodendroglioma. 100% of patients with heterozygous deletions on chromosome 1p/19q were found sensitive to chemotherapy with PVC regimen, with an average survival of 10 years; the average survival of patients without such genetic alterations was only 2 years. The 1p/19q heterozygous deletion is an independent prognostic factor with significant prognosis, even in recurrent cases. 1p/19q heterozygous deletion is a specific molecular genetic alteration in oligodendroglioma, but it is not the only change, so detection of 1p/19q heterozygous deletion is not recommended for differential diagnosis alone. However, for patients with confirmed oligodendroglioma, detection of 1p/19q heterozygous deletions can provide valuable information to clinicians.
References
- Barocas DA, et al. (2006) BJU Int 99: 290-5.
- Gallucci M, et al. (2005) J Clin Pathol 58: 367-71
